# Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

Source: https://onco.cc/trials/nct03155191/  
OnCo record `nct03155191` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TBI-1501 in acute lymphoblastic leukaemia, run by Takara Bio Inc., active and no longer recruiting.

## Summary

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT03155191 by Takara Bio Inc., with 21 participants enrolled, started 2017-06-01 and due to reach its primary completion in 2035-03-31. Interventions recorded: TBI-1501.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03155191
- Phase: 1/2
- Setting: A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia
- Sponsor: Takara Bio Inc.
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT03155191: https://clinicaltrials.gov/study/NCT03155191

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [TBI-1501](https://onco.cc/drugs/tbi-1501/)
- companies: [Takara Bio](https://onco.cc/companies/takara-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct03155191.json